Cheplapharm AG · ISIN: DE000CHP2222 · EQS - Company News

SEBASTIAN BRAUN WINS EY ENTREPRENEUR OF THE YEAR

SEBASTIAN BRAUN WINS EY ENTREPRENEUR OF THE YEAR Greifswald, 08. November 2024 Sebastian Braun wins prestigious entrepreneur award in the ‘family business’ category First award winner from the eastern German states since 2014 The EY Entrepreneur of the Year Award is presented in 60 countries   Sebastian Braun, Chairman of the Supervisory Board, main owner together with his sister Dr Bianca Juha and former CEO of the CHEPLAPHARM Group for many years, is EY Entrepreneur of the Year. He was hon...
About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Cheplapharm AG

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (0)
Short Selling (DE) (0)
Short Selling (UK) (0)
08 November 2024 10:45AM
SEBASTIAN BRAUN WINS EY ENTREPRENEUR OF THE YEAR
DE000CHP2222
SEBASTIAN BRAUN WINS EY ENTREPRENEUR OF THE YEAR Greifswald, 08. November 2024 Sebastian Braun wins prestigious entrepreneur award in the ‘family business’ category First award winner from the eastern German states since 2014 The EY Entrepreneur of the Year Award is presented in 60 countries   Sebastian Braun, Chairman of the Supervisory Board,...
Cheplapharm AG
About the publication
17 July 2024 12:14PM
CHEPLAPHARM reorganises Management Team
DE000CHP2222
Artem Gevorkyan joins as Managing Director Corporate Business Development Karl ‘Charly’ Lang is entrusted with an extended area of responsibility and now leads the Supply Chain & Logistics division across the whole Group Klaus Köhl, previously COO, is leaving the company at his own request The globally active CHEPLAPHARM Group, headquartered ...
Cheplapharm AG
About the publication
26 April 2024 11:55AM
CHEPLAPHARM closes financial year 2023 with record revenue and double-digit growth
DE000CHP2222
CHEPLAPHARM CLOSES FINANCIAL YEAR 2023 WITH RECORD REVENUE AND DOUBLE-DIGIT GROWTH Greifswald, 26th April 2024 Double-digit revenue growth again: +17% YoY to € 1,498.4 million (FY2022: € 1,279.5 million) EBITDA increases significantly by +14% YoY to € 780.5 million (FY2022: € 685.7 million) EBITDA margin remains at a high and industry-leading le...
Cheplapharm AG
About the publication
03 April 2024 10:10AM
Caroline Jacquin appointed Managing Director of CHEPLAPHARM France SAS
DE000CHP2222
Greifswald / Levallois-Perret, 03. April 2024Caroline Jacquin will take over the management of CHEPLAPHARM France, based in Levallois-Perret, a subsidiary of the CHEPLAPHARM Group from Greifswald/Germany, in April 2024. The previous Managing Director of CHEPLAPHARM France, Isabelle Dalle, is retiring. Caroline Jacquin, an experienced pharmaceutica...
Cheplapharm AG
About the publication
18 January 2024 10:13AM
CHEPLAPHARM acquires Roaccutane® from Roche
DE000CHP2222
Binningen, January 18, 2024   The CHEPLAPHARM Group acquires the global rights to Roaccutane® from Roche, thereby strengthening its dermatological portfolio. The medicine, which is based on the active ingredient isotretinoin, is used to treat severe acne.   CHEPLAPHARM, a leading purchaser of originator products from research-based pharmaceutic...
Cheplapharm AG
About the publication
06 November 2023 10:03AM
CHEPLAPHARM opens presence in Tokyo
DE000CHP2222
Greifswald / Tokyo, 6 November 2023   CHEPLAPHARM Arzneimittel GmbH, based in Greifswald/Germany, has opened a presence in the Japanese capital Tokyo and obtained the pharmaceutical licence for Japan. With this, CHEPLAPHARM meets the requirements to be a Marketing Authorisation Holder in Japan. The managing director of the founded CHEPLAPHARM KK i...
Cheplapharm AG
About the publication
21 September 2023 01:41PM
CHEPLAPHARM succesfully places additional notes in a volume of €300m
DE000CHP2222
EQS-Media / 21.09.2023 / 13:41 CET/CEST CHEPLAPHARM Arzneimittel GmbH (“CHEPLAPHARM” or the “Company”), a leading international platform for well-established branded medicines, took advantage of the currently favorable market conditions and successfully placed additional senior secured notes with a total volume of €300m. ...
Cheplapharm AG
About the publication
12 September 2023 10:00AM
CHEPLAPHARM opens swiss subsidiary and wins Agnes Wasem as Managing Director
DE000CHP2222
Agnes Wasem is the Managing Director of the newly founded CHEPLAPHARM Schweiz GmbH CHEPLAPHARM Arzneimittel GmbH, headquartered in Greifswald/Germany, has established a Swiss national subsidiary in Binningen. Managing Director of the newly founded CHEPLAPHARM Schweiz GmbH is Agnes Wasem. Wasem has already held the position since August 1, 2023, an...
Cheplapharm AG
About the publication
28 April 2023 11:12AM
CHEPLAPHARM places notes in a volume of €750m in challenging market environment
DE000CHP2222
CHEPLAPHARM Arzneimittel GmbH (“CHEPLAPHARM”), a leading international platform for well-established branded medicines, announces the successful placement of senior secured notes with a total volume of €750m. The proceeds from the new bonds will be used to finance the acquisition of the worldwide[1] commercial rights for Zyprexa® from Eli Lilly and...
Cheplapharm AG
About the publication
28 April 2023 11:12AM
CHEPLAPHARM places notes in a volume of €750m in challenging market environment
DE000CHP2222
CHEPLAPHARM Arzneimittel GmbH (“CHEPLAPHARM”), a leading international platform for well-established branded medicines, announces the successful placement of senior secured notes with a total volume of €750m. The proceeds from the new bonds will be used to finance the acquisition of the worldwide[1] commercial rights for Zyprexa® from Eli Lilly and...
Cheplapharm AG
About the publication
01 December 2022 10:07AM
Change in the Management of CHEPLAPHARM
DE000CHP2222
Patrick König leaves CHEPLAPHARM at his own request Klaus Köhl becomes new Chief Operating Officer   Patrick König leaves the Company at the end of the year at his own request. Patrick König has worked for CHEPLAPHARM for a total of almost five years. In 2018, the business graduate started at the pharmaceutical company specializing in well-esta...
Cheplapharm AG
About the publication
01 December 2022 10:07AM
Change in the Management of CHEPLAPHARM
DE000CHP2222
Patrick König leaves CHEPLAPHARM at his own request Klaus Köhl becomes new Chief Operating Officer   Patrick König leaves the Company at the end of the year at his own request. Patrick König has worked for CHEPLAPHARM for a total of almost five years. In 2018, the business graduate started at the pharmaceutical company specializing in well-esta...
Cheplapharm AG
About the publication
29 November 2022 01:53PM
CHEPLAPHARM remains on growth track
DE000CHP2222
Double-digit revenue and earnings growth after nine months in 2022 Transformation program launched to optimize organization Significant annual revenue growth planned until 2025   CHEPLAPHARM AG, a leading international platform for well-established branded medicines, remains on growth track. After achieving the highest revenue in the Company's h...
Cheplapharm AG
About the publication
29 November 2022 01:53PM
CHEPLAPHARM remains on growth track
DE000CHP2222
Double-digit revenue and earnings growth after nine months in 2022 Transformation program launched to optimize organization Significant annual revenue growth planned until 2025   CHEPLAPHARM AG, a leading international platform for well-established branded medicines, remains on growth track. After achieving the highest revenue in the Company's h...
Cheplapharm AG
About the publication
25 October 2022 08:34AM
CHEPLAPHARM receives growth capital of EUR 550 million from two leading global investors
DE000CHP2222
Atlantic Park and GIC will invest a total of €550m in CHEPLAPHARM. The transaction will strengthen and diversify CHEPLAPHARM’s financial base and help fuel the Company’s growth. Greifswald, 25 October 2022 -CHEPLAPHARM AG, a leading international platform for well-established branded medicines, today announced that it has entered into a definiti...
Cheplapharm AG
About the publication
25 October 2022 08:34AM
CHEPLAPHARM receives growth capital of EUR 550 million from two leading global investors
DE000CHP2222
Atlantic Park and GIC will invest a total of €550m in CHEPLAPHARM. The transaction will strengthen and diversify CHEPLAPHARM’s financial base and help fuel the Company’s growth. Greifswald, 25 October 2022 -CHEPLAPHARM AG, a leading international platform for well-established branded medicines, today announced that it has entered into a definiti...
Cheplapharm AG
About the publication
29 August 2022 04:06PM
DE000CHP2222
CHEPLAPHARM INCREASES REVENUE AND EARNINGS IN THE FIRST HALF OF 2022   Revenue increases by 20% to €594m in the first half of the year EBITDA grows by 4% to €343m EBITDA margin at 58% Greifswald, 29 August 2022 - CHEPLAPHARM AG, a leading international platform for well-established branded medicines, is continuing its growth path. After achiev...
Cheplapharm AG
About the publication
29 August 2022 04:06PM
CHEPLAPHARM INCREASES REVENUE AND EARNINGS IN THE FIRST HALF OF 2022eplapharm AG:
DE000CHP2222
CHEPLAPHARM INCREASES REVENUE AND EARNINGS IN THE FIRST HALF OF 2022   Revenue increases by 20% to €594m in the first half of the year EBITDA grows by 4% to €343m EBITDA margin at 58% Greifswald, 29 August 2022 - CHEPLAPHARM AG, a leading international platform for well-established branded medicines, is continuing its growth path. After achiev...
Cheplapharm AG
About the publication
29 April 2022 06:37PM
CHEPLAPHARM CONTINUES PROFITABLE GROWTH TRACK IN 2021 AS WELL
DE000CHP2222
- Revenue exceeds €1bn for the first time: +69% YOY to €1,082.0m (FY2020: €639.6m) - EBITDA +86% YOY to €623.9m (FY2020: €335.1m) - Further increased EBITDA margin (58% vs. 52% in FY2020) and gross profit margin (75% vs. 70% in FY2020) demonstrating continued operational leverage with scale - Free cash flow grew by +41% to €371.3m (FY2020: €264....
Cheplapharm AG
About the publication
23 February 2022 10:51AM
Cheplapharm AG: Jens Rothstein hands over his CFO role to Kia Parssanedjad
DE000CHP2222
JENS ROTHSTEIN HANDS OVER HIS CFO ROLE TO KIA PARSSANEDJAD Greifswald, 23 February 2022 - Cheplapharm AG ("Cheplapharm" or "the Company"), a specialty pharmaceutical company which is a global leader in investing in long established and trusted pharma brands and enhancing them with life-cycle-management, today announced a change in senior leadership...
Cheplapharm AG
About the publication
11 February 2022 05:38PM
Cheplapharm AG: CHEPLAPHARM GMBH ANNOUNCES SUCCESSFUL PRICING OF TERM LOAN B
DE000CHP2222
CHEPLAPHARM GMBH ANNOUNCES SUCCESSFUL PRICING OF TERM LOAN B Greifswald, 11 February 2022 Cheplapharm is proud to announce today that it has signed a new term loan facility of €1,480 million. The proceeds from the new term loan facility will be used to roll the Company's existing €980 million term loan facility in full and for general corporate pu...
Cheplapharm AG
About the publication
28 January 2022 01:48PM
Cheplapharm AG: TIMETABLE FOR THE PLANNED IPO IS EXTENDED DUE TO UNFAVORABLE MARKET CONDITIONS
DE000CHP2222
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT DISCLAIMER AT THE END OF THIS RELEASE. CHEPLAPHARM AG: TIMETABLE FOR THE PLANNED IPO IS EXTEN...
Cheplapharm AG
About the publication
17 January 2022 07:46AM
Cheplapharm AG: CHEPLAPHARM AG PLANS FRANKFURT STOCK EXCHANGE LISTING IN Q1 2022
DE000CHP2222
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT DISCLAIMER AT THE END OF THIS RELEASE. CHEPLAPHARM AG PLANS FRANKFURT STOCK EXCHANGE LISTING ...
Cheplapharm Arzneimittel GmbH
About the publication
More Cheplapharm AG related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN